JAMA Dermatology

<jats:sec><jats:title>Importance</jats:title><jats:p>Despite growing interest on the role of diet in the prevention and treatment of psoriasis, randomized clinical trials are lacking. The Mediterranean diet is known for its anti-inflammatory and cardiometabolic benefits, which may be relevant to psoriasis pathophysiology.</jats:p></jats:sec><jats:sec><jats:title>Objective</jats:title><jats:p>To assess whether a 16-week Mediterranean diet intervention would improve psoriasis severity in patients with mild to moderate disease.</jats:p></jats:sec><jats:sec><jats:title>Design, Setting, and Participants</jats:title><jats:p>MEDIPSO (Impact of the Mediterranean Diet on Patients With Psoriasis), an open-label, single-center, single-blinded (evaluator) randomized clinical trial, was conducted from February 2024 to March 2025 at a dermatology referral clinic in Madrid, Spain. Participants were adults with mild to moderate psoriasis (Psoriasis Area and Severity Index [PASI] of 2-10, with higher scores indicating maximal disease) receiving stable topical therapy.</jats:p></jats:sec><jats:sec><jats:title>Interventions</jats:title><jats:p>Participants were randomized 1:1 to the intervention or control group. The intervention group received a 16-week, dietitian-guided Mediterranean diet program, including nutritional counseling, educational materials, and weekly provision of extra virgin olive oil. The control group received standard low-fat dietary advice without dietitian supervision.</jats:p></jats:sec><jats:sec><jats:title>Main Outcomes and Measures</jats:title><jats:p>The primary outcome was the change in the PASI from baseline to week 16. Secondary outcomes included changes in Mediterranean diet adherence, anthropometric and metabolic parameters, serum inflammatory cytokines, and patient-reported outcomes. Estimated marginal means (EMMs) at baseline and for the change from baseline to week 16 were reported, with the intervention effect presented as the between-group difference.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Among 45 individuals screened, 38 participants were enrolled and randomized (mean [SD] age, 46.4 [12.8] years; 25 males [65.8%]); 19 were randomized to the intervention group and 19 were randomized to the control group; 37 individuals (97.4%) completed the study. The EMM PASI change at week 16 was −3.4 (95% CI, −4.4 to −2.4) in the intervention group and 0.0 (95% CI, −1.0 to 1.0) in the control group; the between-group EMM difference was −3.4 (95% CI, −4.8 to −2.0; <jats:italic>P</jats:italic> &amp;amp;lt; .001). Nine of 19 participants in the Mediterranean diet group (47.4%) achieved PASI 75 (a 75% reduction in PASI) compared with none in the control group. A significant reduction in EMM hemoglobin A<jats:sub>1c</jats:sub> (glycated hemoglobin) was observed in the intervention group as compared with the control group (between-group EMM difference, −4.1 mmol/mol [95% CI, −6.9 to −1.3 mmol/mol]; <jats:italic>P</jats:italic> = .01).</jats:p></jats:sec><jats:sec><jats:title>Conclusions and Relevance</jats:title><jats:p>This randomized clinical trial found that a 16-week Mediterranean diet intervention significantly improved psoriasis severity in patients with mild to moderate disease receiving stable topical therapy. These findings suggest that incorporating dietary strategies may be beneficial as an adjunctive therapy in psoriasis management.</jats:p></jats:sec><jats:sec><jats:title>Trial Registration</jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT06257641?term=NCT06257641&amp;amp;amp;rank=1">NCT06257641</jats:ext-link></jats:p></jats:sec>

Psoriasis.

Lancet

The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis.

Clin Rev Allergy Immunol

Psoriasis: from pathogenesis to pharmacological and nano-technological-based therapeutics.

Int J Mol Sci

Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: a systematic review and meta-analysis.

Int J Obes (Lond)

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.

J Am Acad Dermatol

Mediterranean diet pyramid: a cultural model for healthy eating.

Am J Clin Nutr

Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts.

N Engl J Med

Nutrition and psoriasis: is there any association between the severity of the disease and adherence to the Mediterranean diet?

J Transl Med

Association between Mediterranean anti-inflammatory dietary profile and severity of psoriasis: results from the NutriNet-Santé Cohort.

JAMA Dermatol

Adherence to the Mediterranean diet is independently associated with psoriasis risk, severity, and quality of life: a cross-sectional observational study.

Int J Dermatol

Adherence to the Mediterranean diet in patients with psoriasis and its relationship with the severity of the disease: a case-control study.

Health Sci Rep

Adherence to Mediterranean diet in Spanish patients with psoriasis: cardiovascular benefits?

Dermatol Ther

Mediterranean diet and exercise are associated with better disease control in psoriatic arthritis.

Clin Rheumatol

Impact of the Mediterranean diet on patients with psoriasis: protocol for a randomized controlled trial.

JMIR Res Protoc

A remote nutritional intervention to change the dietary habits of patients undergoing ablation of atrial fibrillation: randomized controlled trial.

J Med Internet Res

Validity of the energy-restricted Mediterranean Diet Adherence Screener.

Clin Nutr

10 Years experience of the Dermatology Life Quality Index (DLQI).

J Investig Dermatol Symp Proc

The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response.

Sleep

Measures of depression and depressive symptoms: Beck Depression Inventory-II (BDI-II), Center for Epidemiologic Studies Depression Scale (CES-D), Geriatric Depression Scale (GDS), Hospital Anxiety and Depression Scale (HADS), and Patient Health Questionnaire-9 (PHQ-9).

Arthritis Care Res (Hoboken)

Enhanced multiplexing technology for proteomics.

Annu Rev Anal Chem (Palo Alto Calif)

Aggressive weight-loss program with a ketogenic induction phase for the treatment of chronic plaque psoriasis: a proof-of-concept, single-arm, open-label clinical trial.

Nutrition

Diet and physical exercise in psoriasis: a randomized controlled trial.

Br J Dermatol

The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.

Expert Opin Biol Ther

Polyphenol intake from a Mediterranean diet decreases inflammatory biomarkers related to atherosclerosis: a substudy of the PREDIMED trial.

Br J Clin Pharmacol

The role of diet in modulating inflammation and oxidative stress in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.

Nutrients

Health benefits of the Mediterranean diet: metabolic and molecular mechanisms.

J Gerontol A Biol Sci Med Sci

Consumption of two healthy dietary patterns restored microbiota dysbiosis in obese patients with metabolic dysfunction.

Mol Nutr Food Res

Effect of dietary approaches on glycemic control in patients with type 2 diabetes: a systematic review with network meta-analysis of randomized trials.

Role of lipoprotein(a) in atherosclerotic cardiovascular disease: a review of current and emerging therapies.

Pharmacotherapy

FGF-23 as a biomarker for carotid plaque vulnerability: a systematic review.

Med Sci (Basel)

Fibroblast growth factor 23 and placental growth factor in patients with psoriasis and their relation to disease severity.

Ann Clin Lab Sci

Effects of dietary patterns on biomarkers of inflammation and immune responses: a systematic review and meta-analysis of randomized controlled trials.

Adv Nutr

Despite growing interest on the role of diet in the prevention and treatment of psoriasis, randomized clinical trials are lacking. The Mediterranean diet is known for its anti-inflammatory and cardiometabolic benefits, which may be relevant to psoriasis pathophysiology.
To assess whether a 16-week Mediterranean diet intervention would improve psoriasis severity in patients with mild to moderate disease.
MEDIPSO (Impact of the Mediterranean Diet on Patients With Psoriasis), an open-label, single-center, single-blinded (evaluator) randomized clinical trial, was conducted from February 2024 to March 2025 at a dermatology referral clinic in Madrid, Spain. Participants were adults with mild to moderate psoriasis (Psoriasis Area and Severity Index [PASI] of 2-10, with higher scores indicating maximal disease) receiving stable topical therapy.
Participants were randomized 1:1 to the intervention or control group. The intervention group received a 16-week, dietitian-guided Mediterranean diet program, including nutritional counseling, educational materials, and weekly provision of extra virgin olive oil. The control group received standard low-fat dietary advice without dietitian supervision.
The primary outcome was the change in the PASI from baseline to week 16. Secondary outcomes included changes in Mediterranean diet adherence, anthropometric and metabolic parameters, serum inflammatory cytokines, and patient-reported outcomes. Estimated marginal means (EMMs) at baseline and for the change from baseline to week 16 were reported, with the intervention effect presented as the between-group difference.
Among 45 individuals screened, 38 participants were enrolled and randomized (mean [SD] age, 46.4 [12.8] years; 25 males [65.8%]); 19 were randomized to the intervention group and 19 were randomized to the control group; 37 individuals (97.4%) completed the study. The EMM PASI change at week 16 was -3.4 (95% CI, -4.4 to -2.4) in the intervention group and 0.0 (95% CI, -1.0 to 1.0) in the control group; the between-group EMM difference was -3.4 (95% CI, -4.8 to -2.0; P < .001). Nine of 19 participants in the Mediterranean diet group (47.4%) achieved PASI 75 (a 75% reduction in PASI) compared with none in the control group. A significant reduction in EMM hemoglobin A1c (glycated hemoglobin) was observed in the intervention group as compared with the control group (between-group EMM difference, -4.1 mmol/mol [95% CI, -6.9 to -1.3 mmol/mol]; P = .01).
This randomized clinical trial found that a 16-week Mediterranean diet intervention significantly improved psoriasis severity in patients with mild to moderate disease receiving stable topical therapy. These findings suggest that incorporating dietary strategies may be beneficial as an adjunctive therapy in psoriasis management.
ClinicalTrials.gov Identifier: NCT06257641.

Mediterranean Diet and Patients With Psoriasis: The MEDIPSO Randomized Clinical Trial.

Mediterranean Diet and Patients With Psoriasis

Papers